|  |  |  |
| --- | --- | --- |
| |  |  | | --- | --- | | Complimentary CME/CE Programs | Is this email not displaying correctly? [View it in your browser](file:///C:\Users\Niki%20Bossonis\OneDrive%20-%20Rockpointe%20Corporation\Documents\Campaigns2021\1057-1058-LDL-C\%7b%7bView_Online%7d%7d). | |

|  |  |
| --- | --- |
| |  | | --- | | **[A picture containing diagram  Description automatically generated](https://cme.rockpointe.com/1058-wbc-optimizing-ldl-c-individualizing-treatment-using-statins-and-nonstatin-therapy)** | |
| |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  | | --- | --- | --- | --- | --- | | [**Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy**](https://cme.rockpointe.com/1058-wbc-optimizing-ldl-c-individualizing-treatment-using-statins-and-nonstatin-therapy)  **Course Type:**On-Demand Webcourse  **Number of Credits:**1 **Credit Type**: CME/MOC/MIPS   [A picture containing text  Description automatically generated](https://cme.rockpointe.com/1058-wbc-optimizing-ldl-c-individualizing-treatment-using-statins-and-nonstatin-therapy)  ***Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy***will  review how to use the risk assessment tool, the 2018 LDL-C guidelines recommendations including the role of the non-statin agents ezetimibe and PCSK9 inhibitors. Expert faculty will discuss the role of bempedoic acid, an agent recently approved for LDL-C management, as well as results from trials of inclisiran, an agent in late-stage development.  **FACULTY**   |  |  | | --- | --- | | **A close-up of a person smiling  Description automatically generated Rachel M. Bond, MD, FACC**  System Director, Women’s Heart Health  Dignity Health, Arizona  Chandler, AZ | **A person wearing a white shirt and blue tie  Description automatically generated with medium confidence  Ty J. Gluckman, MD, FACC, FAHA**  Medical Director, Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute  Providence St. Joseph Health  Portland, OR  Adjunct Faculty, Ciccarone Center for the Prevention of Heart Disease  Johns Hopkins Hospital  Baltimore, MD | |  |  |     [A picture containing text  Description automatically generated](https://cme.rockpointe.com/1058-wbc-optimizing-ldl-c-individualizing-treatment-using-statins-and-nonstatin-therapy)  **PROVIDER**  Jointly provided by the Potomac Center for Medical Education Health and Rockpointe  Logo, company name  Description automatically generated  Physician CME  **SUPPORTER**  This activity is supported by educational funding provided by Amgen and Esperion. | | **Thank you for choosing Rockpointe for your CME activities. We appreciate your participation in our programs.** | | | |
| |  |  |  |  |  | | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | [follow on Twitter](https://twitter.com/RockpointeCorp) | [friend on Facebook](https://www.facebook.com/RockpointeCorp/) | [forward to a friend](file:///C:\Users\Niki%20Bossonis\OneDrive%20-%20Rockpointe%20Corporation\Documents\Campaigns2021\1057-1058-LDL-C\%7b%7baddthis_url_email%7d%7d)  [**www.Rockpointe.com**](https://rockpointe.com) | | | *Copyright © 2021, All rights reserved.*  **Our mailing address is:**  Rockpointe Corporation 8335 Guilford Road Suite A Columbia, MD 21046 |  | | |